| Literature DB >> 33936204 |
Hui-Jing Chen1,2, Yue Yu3, Yan-Xia Sun3, Chuan-Zhong Huang1,2, Jie-Yu Li1,2, Fang Liu1,2, Guo-Xiang Guo3, Yun-Bin Ye1,2,3.
Abstract
Id4 is one of the inhibitors of DNA-binding proteins (Id) and involved in the pathogenesis of numerous cancers. The specific mechanism underlying the Id4-mediated regulation of proliferation, invasion, and metastasis of colorectal cancer (CRC) cells is still largely unclear. In the present study, results showed CRC cells had a lower baseline Id4 expression than normal intestinal epithelial NCM460 cells. In order to explore the role of Id4 in the tumorigenicity, CRC HCT116 cells with stable Id4 expression were used, and results showed Id4 overexpression arrested the cell cycle at the G0/G1 phase, inhibited the cell proliferation and the colony formation, as well as suppressed the migration and invasion. In the in vivo model, Id4 overexpression inhibited the tumor growth and metastasis in the nude mice. Furthermore, Id4 overexpression upregulated the expression of proteins associated with cell proliferation, inhibited the PI3K/AKT pathway, and suppressed epithelial-mesenchymal transition (EMT) of HCT116 cells. Moreover, Id4 significantly decreased cytokeratin 18 (CK18) expression, but CK18 overexpression in Id4 expressing HCT116-Id4 cells rescued the activation of AKT, p-AKT, MMP2, MMP7, and E-cadherin. Collectively, our study indicated Id4 may inhibit CRC growth and metastasis through inhibiting the PI3K/AKT pathway in a CK18-dependent manner and suppressing EMT. Id4 may become a target for the treatment of CRC.Entities:
Year: 2021 PMID: 33936204 PMCID: PMC8060092 DOI: 10.1155/2021/6660486
Source DB: PubMed Journal: J Oncol ISSN: 1687-8450 Impact factor: 4.375
Figure 1Id4 overexpression reduces cell proliferation and arrests cell cycle at the G0/G1 phase. (a) Id4 protein expression in the CRC. (b, c) Real-time RT-PCR and Western blotting confirmed stable Id4 overexpression in the HCT116 cells. β-Actin was used as a loading control. (d) WST assay was used to assess the effect of Id4 on the proliferation of HCT116 cells. (e) Colony formation assay was used to assess the effect of Id4 on the colony-forming ability of the HCT116 cells. (f) Flow cytometry was performed to detect the cell cycle after Id4 overexpression. (g) Photographs of the xenograft tumors in the nude mice at day 14 after implantation, and tumor weight was measured. (h) Protein expression of molecules in the PI3K/AKT pathway and proliferation-related proteins in the HCT116-Id4 cells (Western blotting). GAPDH was used as a loading control. Data are expressed as mean ± SD. P < 0.05.
Figure 2Id4 regulated the migration, invasion, and metastatic potentials of CRC cells. (a) Wound healing assay of CRC cells. (b) Migration assay of CRC cells (Boyden chamber assay). (c) Invasion assay of CRC cells (Boyden chamber assay). (d) Intrasplenic implantation of HCT116-Id4 cells or control cells. The number of tumors in the spleens and liver metastases of the HCT116-Id4 group decreased significantly.
Figure 3Id4 regulated the expression of EMT-related markers in the HCT116 cells. (a) The expression of EMT-related molecules in the HCT116-Id4 cells and control cells (Western blotting). (b) Cellular morphology of HCT116-Id4 cells and control cells under microscopy.
Figure 4Id4 binding to CK18 regulated the PI3K pathway and the expression of EMT-related markers. (a) Coomassie blue-stained SDS-PAGE gel showed the protein binding to Id4 (flag). (b) Co-IP assay showed the interaction between Id4 and CK18 in the HCT116 cells. (c) Id4 decreased CK18 protein expression (Western blotting). (d) HCT116-Id4 cells and negative control cells were transfected with CK18 plasmid or control plasmid, respectively. Western blotting was performed to investigate the effect of CK18 on the expression of EMT-related markers in the HCT116 cells.